Voyager Therapeutics (NASDAQ:VYGR) Now Covered by Cantor Fitzgerald

Cantor Fitzgerald started coverage on shares of Voyager Therapeutics (NASDAQ:VYGR) in a report published on Friday, Marketbeat Ratings reports. The brokerage issued an overweight rating and a $5.73 target price on the stock.

Several other brokerages also recently weighed in on VYGR. Leerink Partners assumed coverage on shares of Voyager Therapeutics in a research note on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 target price on the stock. StockNews.com lowered shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. Leerink Partnrs upgraded Voyager Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 16th. Wedbush assumed coverage on Voyager Therapeutics in a report on Friday, November 29th. They issued an “outperform” rating and a $11.00 price target on the stock. Finally, HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of Voyager Therapeutics in a report on Thursday, November 14th. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $15.97.

Voyager Therapeutics Price Performance

Shares of NASDAQ VYGR opened at $5.45 on Friday. The stock has a market capitalization of $297.71 million, a P/E ratio of 7.68 and a beta of 0.93. Voyager Therapeutics has a 1-year low of $5.19 and a 1-year high of $10.66. The business’s 50 day moving average is $6.13 and its two-hundred day moving average is $6.84.

Voyager Therapeutics (NASDAQ:VYGR) last released its earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.29. The firm had revenue of $24.63 million for the quarter, compared to the consensus estimate of $12.63 million. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. During the same quarter in the previous year, the company posted ($0.59) EPS. As a group, equities research analysts anticipate that Voyager Therapeutics will post -0.89 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, COO Robin Swartz sold 6,500 shares of the company’s stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $5.65, for a total value of $36,725.00. Following the completion of the sale, the chief operating officer now directly owns 112,328 shares of the company’s stock, valued at $634,653.20. This represents a 5.47 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 4.53% of the company’s stock.

Institutional Investors Weigh In On Voyager Therapeutics

Several large investors have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. increased its holdings in Voyager Therapeutics by 64.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,489 shares of the company’s stock valued at $61,000 after buying an additional 4,098 shares during the period. Intech Investment Management LLC purchased a new position in shares of Voyager Therapeutics in the 3rd quarter valued at $74,000. Victory Capital Management Inc. raised its position in shares of Voyager Therapeutics by 14.5% in the 2nd quarter. Victory Capital Management Inc. now owns 12,892 shares of the company’s stock worth $102,000 after acquiring an additional 1,630 shares in the last quarter. Hsbc Holdings PLC purchased a new stake in shares of Voyager Therapeutics during the 2nd quarter worth $128,000. Finally, Verition Fund Management LLC bought a new stake in Voyager Therapeutics during the third quarter valued at about $216,000. Institutional investors own 48.03% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.